IU Health and the Indiana University Melvin and Bren Simon Comprehensive Cancer Center plans to develop a state-wide mobile lung cancer screening program as a result of a $4.5 million gift from The Tom and Julie Wood Family Foundation, which includes $4 million matching dollars from Indiana University Health.
Lung Cancer Awareness Month kicked off this week, and this is a monumental one for us at the American Cancer Society.
A study demonstrated that viral immune evasion enabled breakthrough infections of COVID-19 in patients with lung cancer, highlighting the importance of effective monitoring mechanisms, such as anti-N serology, to track infection rates in specific vulnerable populations.
FirstLook Lung, a blood test that offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT with a negative predictive value of 99.7%, was commercially introduced.
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
The FDA Oncologic Drugs Advisory Committee concurred with the FDA staff that the Amgen Inc. confirmatory trial of the lung cancer therapy sotorasib (Lumakras) was uninterpretable as a result of a perceived loss of equipoise.
Taofeek K. Owonikoko, a physician-scientist and thoracic oncologist, was named executive director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).
Thoracic surgeons and researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that increasing numbers of patients undergoing cancer-removal lung surgery by “anatomic lung resections”—lobectomies or segmentectomies—are able to go home safely and without complications one day after the operation, thanks to growing rates of robot-assisted surgeries and improvements in patient-centered care protocols.
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung Cancer Master Protocol, or Lung-MAP, has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant setting for early-stage non-small-cell lung cancer, according to researchers at MD Anderson Cancer Center.
